Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer

被引：0
|
作者：
Zhang, Yan
Wang, Yan
Li, Junling
Hao, Xuezhi
Ma, Di
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Beijing 100021, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Cardiac toxicity; crizotinib; NSCLC; CK-MB elevation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI31.07
引用
收藏
页码：S377 / S377
页数：1
相关论文
共 50 条
  • [1] Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer
    Qi, Xiaolong
    Ma, Wang
    Li, Sen
    Zhou, Caicun
    LUNG CANCER, 2014, 85 (02) : 335 - 336
  • [2] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
  • [3] Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
    Gandhi, Leena
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3737 - 3742
  • [4] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
    Cappuzzo, Federico
    Moro-Sibilot, Denis
    Gautschi, Oliver
    Boleti, Ekaterini
    Felip, Enriqueta
    Groen, Harry J. M.
    Germonpre, Paul
    Meldgaard, Peter
    Arriola, Edurne
    Steele, Nicola
    Fox, Jesme
    Schnell, Patrick
    Engelsberg, Arne
    Wolf, Juergen
    LUNG CANCER, 2015, 87 (02) : 89 - 95
  • [5] Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
    van der Wekken, Anthonie J.
    Kok, Klaas
    Groen, Harry J. M.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2130 - S2132
  • [6] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    TUMORI JOURNAL, 2016, 102 : S46 - S49
  • [7] THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
    Noma, Daisuke
    Sakamoto, Kazuhiro
    Ando, Kohei
    Amano, Shinya G.
    Sudo, Shigeto
    Goto, Hideto
    Yamakawa, Yasushi
    Tsubakihara, Motofumi
    Tsuboi, Masahiro
    Masuda, Munetaka
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1320 - S1320
  • [8] ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?
    Audigier-Vaiette, Clarisse
    Girard, Nicolas
    Cortot, Alexis B.
    Mennecier, Bertrand
    Debieuvre, Didier
    Planchard, David
    Zalcman, Gerard
    Moro-Sibilot, Denis
    Cadranel, Jacques
    Barlesi, Fabrice
    BULLETIN DU CANCER, 2014, 101 (09) : 823 - 831
  • [9] Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer
    Leprieur, Etienne Giroux
    Wislez, Marie
    BULLETIN DU CANCER, 2016, 103 (02) : 125 - +
  • [10] Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
    Ito, Kentaro
    Hataji, Osamu
    Kobayashi, Hiroyasu
    Fujiwara, Atsushi
    Yoshida, Masamichi
    D'Alessandro-Gabazza, Corina N.
    Itani, Hidetoshi
    Tanigawa, Motoaki
    Ikeda, Takuya
    Fujiwara, Kentaro
    Fujimoto, Hajime
    Kobayashi, Tetsu
    Gabazza, Esteban C.
    Taguchi, Osamu
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 390 - 396
12345